Knee Osteoarthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major knee osteoarthritis markets reached a value of US$ 4.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 9.1 Billion by 2034, exhibiting a growth rate (CAGR) of 6.18% during 2024-2034.
The knee osteoarthritis market has been comprehensively analyzed in IMARC's new report titled "Knee Osteoarthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Knee osteoarthritis, also referred to as degenerative joint disease, is a condition characterized by the slow deterioration of connective tissues in the knee joint. As the illness progresses, the joint may become inflamed, and bony growths called bone spurs may develop in the affected area. These changes can result in pain, swelling, and difficulty performing daily functions, such as climbing stairs, walking, or bending the knee. The symptoms of the ailment can vary from person to person but commonly include stiffness, grating or popping sensations, reduced range of motion, muscle weakness, instability, etc. The diagnosis of this disorder typically involves a combination of characteristic findings, medical history, and physical examination. The healthcare provider may also perform X-rays to visualize the knee and assess the extent of joint damage. In some cases, numerous other imaging tests, such as computed tomography (CT) scans or magnetic resonance imaging (MRI), may be recommended to obtain more detailed information about the joint structures. Furthermore, an arthrocentesis is conducted to confirm the diagnosis in individuals suffering from the disease.
The increasing cases of structural abnormalities in the knee joint, such as malalignment or instability that can lead to an uneven distribution of forces across the joint surfaces, causing cartilage damage, are primarily driving the knee osteoarthritis market. In addition to this, the expanding geriatric population, who are prone to degenerative changes due to reduced tissue repair capacity, is also creating a positive outlook for the market. Moreover, the widespread adoption of physical therapy, owing to its various advantages, like strengthening the muscles around the knee joint, improving flexibility, and offering pain relief to patients, is further bolstering the market growth. Apart from this, the inflating application of assistive devices, including canes, crutches, braces, etc., that help to reduce stress on the joint and provide support during movement is acting as another significant growth-inducing factor. Additionally, the emerging popularity of hyaluronic acid injections, since they improve the viscoelastic properties of the synovial fluid, thereby decreasing friction between the bones, is expected to drive the knee osteoarthritis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the knee osteoarthritis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for knee osteoarthritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the knee osteoarthritis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the knee osteoarthritis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the knee osteoarthritis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current knee osteoarthritis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the knee osteoarthritis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the knee osteoarthritis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the knee osteoarthritis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of knee osteoarthritis across the seven major markets?
What is the number of prevalent cases (2018-2034) of knee osteoarthritis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of knee osteoarthritis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with knee osteoarthritis across the seven major markets?
What is the size of the knee osteoarthritis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of knee osteoarthritis?
What will be the growth rate of patients across the seven major markets?
Knee Osteoarthritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for knee osteoarthritis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the knee osteoarthritis market?
What are the key regulatory events related to the knee osteoarthritis market?
What is the structure of clinical trial landscape by status related to the knee osteoarthritis market?
What is the structure of clinical trial landscape by phase related to the knee osteoarthritis market?
What is the structure of clinical trial landscape by route of administration related to the knee osteoarthritis market?
The knee osteoarthritis market has been comprehensively analyzed in IMARC's new report titled "Knee Osteoarthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Knee osteoarthritis, also referred to as degenerative joint disease, is a condition characterized by the slow deterioration of connective tissues in the knee joint. As the illness progresses, the joint may become inflamed, and bony growths called bone spurs may develop in the affected area. These changes can result in pain, swelling, and difficulty performing daily functions, such as climbing stairs, walking, or bending the knee. The symptoms of the ailment can vary from person to person but commonly include stiffness, grating or popping sensations, reduced range of motion, muscle weakness, instability, etc. The diagnosis of this disorder typically involves a combination of characteristic findings, medical history, and physical examination. The healthcare provider may also perform X-rays to visualize the knee and assess the extent of joint damage. In some cases, numerous other imaging tests, such as computed tomography (CT) scans or magnetic resonance imaging (MRI), may be recommended to obtain more detailed information about the joint structures. Furthermore, an arthrocentesis is conducted to confirm the diagnosis in individuals suffering from the disease.
The increasing cases of structural abnormalities in the knee joint, such as malalignment or instability that can lead to an uneven distribution of forces across the joint surfaces, causing cartilage damage, are primarily driving the knee osteoarthritis market. In addition to this, the expanding geriatric population, who are prone to degenerative changes due to reduced tissue repair capacity, is also creating a positive outlook for the market. Moreover, the widespread adoption of physical therapy, owing to its various advantages, like strengthening the muscles around the knee joint, improving flexibility, and offering pain relief to patients, is further bolstering the market growth. Apart from this, the inflating application of assistive devices, including canes, crutches, braces, etc., that help to reduce stress on the joint and provide support during movement is acting as another significant growth-inducing factor. Additionally, the emerging popularity of hyaluronic acid injections, since they improve the viscoelastic properties of the synovial fluid, thereby decreasing friction between the bones, is expected to drive the knee osteoarthritis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the knee osteoarthritis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for knee osteoarthritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the knee osteoarthritis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the knee osteoarthritis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the knee osteoarthritis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current knee osteoarthritis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the knee osteoarthritis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the knee osteoarthritis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the knee osteoarthritis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of knee osteoarthritis across the seven major markets?
What is the number of prevalent cases (2018-2034) of knee osteoarthritis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of knee osteoarthritis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with knee osteoarthritis across the seven major markets?
What is the size of the knee osteoarthritis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of knee osteoarthritis?
What will be the growth rate of patients across the seven major markets?
Knee Osteoarthritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for knee osteoarthritis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the knee osteoarthritis market?
What are the key regulatory events related to the knee osteoarthritis market?
What is the structure of clinical trial landscape by status related to the knee osteoarthritis market?
What is the structure of clinical trial landscape by phase related to the knee osteoarthritis market?
What is the structure of clinical trial landscape by route of administration related to the knee osteoarthritis market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 KNEE OSTEOARTHRITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 KNEE OSTEOARTHRITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 KNEE OSTEOARTHRITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 KNEE OSTEOARTHRITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 KNEE OSTEOARTHRITIS - UNMET NEEDS
10 KNEE OSTEOARTHRITIS - KEY ENDPOINTS OF TREATMENT
11 KNEE OSTEOARTHRITIS - MARKETED PRODUCTS
11.1 List of Knee Osteoarthritis Marketed Drugs Across the Top 7 Markets
11.1.1 Pennsaid (Diclofenac transdermal first generation) - Crescita Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Zilretta (Triamcinolone acetonide sustained release) - Flexion Therapeutics
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Supartz (Sodium hyaluronate)
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 TriVISC (Sodium hyaluronate) - OrthogenRx
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 KNEE OSTEOARTHRITIS - PIPELINE DRUGS
12.1 List of Knee Osteoarthritis Pipeline Drugs Across the Top 7 Markets
12.1.1 Lorecivivint - Biosplice Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 DFV 890 - Novartis
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 LNA 043 - Novartis
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 PPV-06 - Peptinov
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 GNSC 001 - Genascence Corporation
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. KNEE OSTEOARTHRITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. KNEE OSTEOARTHRITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 KNEE OSTEOARTHRITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Knee Osteoarthritis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Knee Osteoarthritis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Knee Osteoarthritis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Knee Osteoarthritis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Knee Osteoarthritis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Knee Osteoarthritis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Knee Osteoarthritis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Knee Osteoarthritis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Knee Osteoarthritis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Knee Osteoarthritis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Knee Osteoarthritis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Knee Osteoarthritis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Knee Osteoarthritis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Knee Osteoarthritis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Knee Osteoarthritis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Knee Osteoarthritis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Knee Osteoarthritis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Knee Osteoarthritis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Knee Osteoarthritis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Knee Osteoarthritis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Knee Osteoarthritis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Knee Osteoarthritis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Knee Osteoarthritis - Access and Reimbursement Overview
16 KNEE OSTEOARTHRITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 KNEE OSTEOARTHRITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 KNEE OSTEOARTHRITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 KNEE OSTEOARTHRITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 KNEE OSTEOARTHRITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 KNEE OSTEOARTHRITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 KNEE OSTEOARTHRITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 KNEE OSTEOARTHRITIS - UNMET NEEDS
10 KNEE OSTEOARTHRITIS - KEY ENDPOINTS OF TREATMENT
11 KNEE OSTEOARTHRITIS - MARKETED PRODUCTS
11.1 List of Knee Osteoarthritis Marketed Drugs Across the Top 7 Markets
11.1.1 Pennsaid (Diclofenac transdermal first generation) - Crescita Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Zilretta (Triamcinolone acetonide sustained release) - Flexion Therapeutics
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Supartz (Sodium hyaluronate)
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 TriVISC (Sodium hyaluronate) - OrthogenRx
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 KNEE OSTEOARTHRITIS - PIPELINE DRUGS
12.1 List of Knee Osteoarthritis Pipeline Drugs Across the Top 7 Markets
12.1.1 Lorecivivint - Biosplice Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 DFV 890 - Novartis
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 LNA 043 - Novartis
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 PPV-06 - Peptinov
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 GNSC 001 - Genascence Corporation
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. KNEE OSTEOARTHRITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. KNEE OSTEOARTHRITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 KNEE OSTEOARTHRITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Knee Osteoarthritis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Knee Osteoarthritis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Knee Osteoarthritis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Knee Osteoarthritis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Knee Osteoarthritis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Knee Osteoarthritis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Knee Osteoarthritis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Knee Osteoarthritis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Knee Osteoarthritis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Knee Osteoarthritis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Knee Osteoarthritis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Knee Osteoarthritis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Knee Osteoarthritis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Knee Osteoarthritis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Knee Osteoarthritis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Knee Osteoarthritis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Knee Osteoarthritis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Knee Osteoarthritis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Knee Osteoarthritis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Knee Osteoarthritis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Knee Osteoarthritis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Knee Osteoarthritis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Knee Osteoarthritis - Access and Reimbursement Overview
16 KNEE OSTEOARTHRITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 KNEE OSTEOARTHRITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 KNEE OSTEOARTHRITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
